David T W Wong
Overview
Explore the profile of David T W Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
4118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kamounah S, Wei F, Park J, Song Y, Chia D, Wong D, et al.
Biochim Biophys Acta Mol Basis Dis
. 2024 Apr;
1870(5):167168.
PMID: 38641012
Objectives: Testing for anti-SSA/Ro antibodies in serum is essential in the diagnostic work-up for primary Sjögren's syndrome (pSS). In this study, we aimed to validate our previous assay for detection...
12.
Chiang S, Grogan T, Kamounah S, Wei F, Tayob N, Kim J, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38599651
Objective: Primary Sjögren's syndrome (pSS) is the second most common chronic autoimmune connective tissue disease. Autoantibodies, immunoglobulin (IgG) anti-SSA/Ro, in serum is a key diagnostic feature of pSS. Since pSS...
13.
Bansal A, Naidu S, Figueiredo N, Alrabiah M, Hamli H, Wong D, et al.
Ophthalmol Retina
. 2024 Mar;
8(7):727-729.
PMID: 38527570
No abstract available.
14.
Cheng J, Swarup N, Wong D, Chia D
Front Oncol
. 2024 Mar;
14:1332004.
PMID: 38511142
In clinical oncology, cell-free DNA (cfDNA) has shown immense potential in its ability to noninvasively detect cancer at various stages and monitor the progression of therapy. Despite the rapid improvements...
15.
Mohammadi A, Chiang S, Li F, Wei F, Lau C, Aziz M, et al.
Res Sq
. 2024 Jan;
PMID: 38234820
We developed a 4-parameter clinical assay using Electric Field Induced Release and Measurement (EFIRM) technology to simultaneously assess SARS-CoV-2 RNA (vRNA), nucleocapsid antigen, host binding (BAb) and neutralizing antibody (NAb)...
16.
Swarup N, Cheng J, Choi I, Heo Y, Kordi M, Aziz M, et al.
Biomark Res
. 2023 Nov;
11(1):96.
PMID: 37946258
No abstract available.
17.
Swarup N, Cheng J, Choi I, Heo Y, Kordi M, Aziz M, et al.
Biomark Res
. 2023 Oct;
11(1):90.
PMID: 37817261
Background: Recent advances in circulating cell-free DNA (cfDNA) analysis from biofluids have opened new avenues for liquid biopsy (LB). However, current cfDNA LB assays are limited by the availability of...
18.
Batool S, Hsia T, Beecroft A, Lewis B, Ekanayake E, Rosenfeld Y, et al.
Cell Rep Med
. 2023 Sep;
4(10):101196.
PMID: 37725979
Liquid biopsy, through isolation and analysis of disease-specific analytes, has evolved as a promising tool for safe and minimally invasive diagnosis and monitoring of tumors. It also has tremendous utility...
19.
Cheng J, Swarup N, Li F, Kordi M, Lin C, Yang S, et al.
Clin Chem
. 2023 Sep;
69(11):1270-1282.
PMID: 37725931
Background: Using broad range cell-free DNA sequencing (BRcfDNA-Seq), a nontargeted next-generation sequencing (NGS) methodology, we previously identified a novel class of approximately 50 nt ultrashort single-stranded cell-free DNA (uscfDNA) in...
20.
The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring
Batool S, Yekula A, Khanna P, Hsia T, Gamblin A, Ekanayake E, et al.
Cell Rep Med
. 2023 Sep;
4(10):101198.
PMID: 37716353
The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis,...